FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Samia Mora

Research Profile

Disorders

Concepts & Ideas

Chemicals & Drugs

Procedures

Double-Blind Method

Co-author Network

Publications

TOP 3
Samia Mora
Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels.
Samia Mora; Børge G Nordestgaard; S Matthijs Boekholdt; Robert J Glynn; John J P Kastelein; Paul M Ridker
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Samia Mora; Nanette K Wenger; Benoit J Arsenault; S Matthijs Boekholdt; Andrei Breazna; Prakash Deedwania; David A Demicco; John J P Kastelein; David D Waters
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Samia Mora (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Samia Mora
Non-fasting blood testing for lipid screening in children result in statistically significant, but not clinically significant, changes in lipid levels.
Evidence-based medicine 2012;17(4):133-4.
2012: Samia Mora; Børge G Nordestgaard; S Matthijs Boekholdt; Robert J Glynn; John J P Kastelein; Paul M Ridker
On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
Journal of the American College of Cardiology 2012;59(17):1521-8.
2012: Samia Mora; Nanette K Wenger; Benoit J Arsenault; S Matthijs Boekholdt; Andrei Breazna; Prakash Deedwania; David A Demicco; John J P Kastelein; David D Waters
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study.
Circulation 2012;125(16):1979-87.
2012: Samia Mora
Aspirin therapy in primary prevention: comment on "effect of aspirin on vascular and nonvascular outcomes".
Archives of internal medicine 2012;172(3):217-8.
2010: Samia Mora; Pia R Kamstrup; Nader Rifai; Børge G Nordestgaard; Julie E Buring; Paul M Ridker
Lipoprotein(a) and risk of type 2 diabetes.
Clinical chemistry 2010;56(8):1252-60.
2010: Paul M Ridker; Jacques Genest; S Matthijs Boekholdt; Peter Libby; Antonio M Gotto; Børge G Nordestgaard; Samia Mora; Jean G MacFadyen; Robert J Glynn; John J P Kastelein
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial.
Lancet 2010;376(9738):333-9.
2010: Sandra A Weiss; Roger S Blumenthal; ALBERT SHARRETT; Rita F Redberg; Samia Mora
Exercise blood pressure and future cardiovascular death in asymptomatic individuals.
Circulation 2010;121(19):2109-16.
2010: Samia Mora; James D Otvos; Robert S Rosenson; Aruna Pradhan; Julie E Buring; Paul M Ridker
Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women.
Diabetes 2010;59(5):1153-60.
2010: Samia Mora; Robert J Glynn; Judith Hsia; Jean G MacFadyen; Jacques Genest; Paul M Ridker
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
Circulation 2010;121(9):1069-77.
2009: Daniel I Chasman; Guillaume Paré; Samia Mora; Jemma C Hopewell; Gina Peloso; Robert Clarke; L Adrienne Cupples; Anders Hamsten; Sekar Kathiresan; Anders Mälarstig; José M Ordovas; Samuli Ripatti; Alex N Parker; JP Miletich; Paul M Ridker
Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis.
PLoS genetics 2009;5(11):e1000730.
2009: Samia Mora
Advanced lipoprotein testing and subfractionation are not (yet) ready for routine clinical use.
Circulation 2009;119(17):2396-404.
2009: Samia Mora; James D Otvos; Nader Rifai; Robert S Rosenson; Julie E Buring; Paul M Ridker
Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women.
Circulation 2009;119(7):931-9.
2008: Samia Mora; Nader Rifai; Julie E Buring; Paul M Ridker
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.
Circulation 2008;118(10):993-1001.
2007: Samia Mora; Nancy Cook; Julie E Buring; Paul M Ridker; I-Min Lee
Physical activity and reduced risk of cardiovascular events: potential mediating mechanisms.
Circulation 2007;116(19):2110-8.
2007: Sandeep Bansal; Julie E Buring; Nader Rifai; Samia Mora; Frank M Sacks; Paul M Ridker
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women.
JAMA : the journal of the American Medical Association 2007;298(3):309-16.
2007: Robert Y L Zee; Samia Mora; Suzanne Cheng; Henry A Erlich; Klaus Lindpaintner; Nader Rifai; Julie E Buring; Paul M Ridker
Homocysteine, 5,10-methylenetetrahydrofolate reductase 677C>T polymorphism, nutrient intake, and incident cardiovascular disease in 24,968 initially healthy women.
Clinical chemistry 2007;53(5):845-51.
2007: Samia Mora; Moyses Szklo; James D Otvos; Philip Greenland; Bruce M Psaty; David C Goff; Daniel H O'Leary; Mohammed F Saad; Michael Y Tsai; ALBERT SHARRETT
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis 2007;192(1):211-7.
2006: Stasia Stott Reynolds; Lisa R Yanek; Dhananjay Vaidya; Samia Mora; Taryn F Moy; Christopher D Saudek; Lewis C Becker; Diane M Becker
Glucose levels in the normal range predict incident diabetes in families with premature coronary heart disease.
Diabetes research and clinical practice 2006;74(3):267-73.
2006: Samia Mora; Nader Rifai; Julie E Buring; Paul M Ridker
Additive value of immunoassay-measured fibrinogen and high-sensitivity C-reactive protein levels for predicting incident cardiovascular events.
Circulation 2006;114(5):381-7.
2006: Samia Mora; I-Min Lee; Julie E Buring; Paul M Ridker
Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women.
JAMA : the journal of the American Medical Association 2006;295(12):1412-9.
2005: Samia Mora; Rita F Redberg; ALBERT SHARRETT; Roger S Blumenthal
Enhanced risk assessment in asymptomatic individuals with exercise testing and Framingham risk scores.
Circulation 2005;112(11):1566-72.
2005: Samia Mora; Lisa R Yanek; Taryn F Moy; MARGARET D FALLIN; Lewis C Becker; Diane M Becker
Interaction of body mass index and framingham risk score in predicting incident coronary disease in families.
Circulation 2005;111(15):1871-6.
2003: Samia Mora; Rita F Redberg; Yadong Cui; Maura K Whiteman; Jodi A Flaws; ALBERT SHARRETT; Roger S Blumenthal
Ability of exercise testing to predict cardiovascular and all-cause death in asymptomatic women: a 20-year follow-up of the lipid research clinics prevalence study.
JAMA : the journal of the American Medical Association 2003;290(12):1600-7.